HC Wainwright & Co. Reiterates Buy on CARISMA Therapeutics, Maintains $8 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Mitchell Kapoor has reiterated a Buy rating on CARISMA Therapeutics (NASDAQ:CARM) and maintained a price target of $8.
June 26, 2024 | 4:22 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. analyst Mitchell Kapoor has reiterated a Buy rating on CARISMA Therapeutics and maintained a price target of $8.
The reiteration of a Buy rating and the maintenance of a price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100